Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 21 2023 - 08:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to achieve FDA approval for the first ophthalmic
formulation of bevacizumab for the treatment of retinal diseases,
today announced that Russell Trenary, President and CEO of Outlook
Therapeutics will participate in a panel presentation at the 2023
Cantor Fitzgerald Global Healthcare Conference being held in New
York, NY on Tuesday, September 26, 2023 at 1:35 PM ET.
In addition to the panel presentation,
management will be available to participate in in-person one-on-one
meetings with qualified members of the investor community who are
registered to attend the conference. For more information about the
conference, please visit the conference website.
A live video webcast of the panel presentation
will be accessible on the Events page in the Investors section of
the Company’s website (outlooktherapeutics.com). A webcast replay
will be archived for 90 days following the event.
About Outlook Therapeutics,
Inc.Outlook Therapeutics is a biopharmaceutical company
working to achieve FDA approval for the launch of ONS-5010/
LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic
formulation of bevacizumab for use in retinal indications,
including wet AMD, DME and BRVO. The FDA accepted Outlook
Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with an
initial PDUFA goal date of August 29, 2023; FDA did not approve the
BLA during this review cycle and the Company is working with the
FDA to address the issues that have been raised so that the BLA may
be re-submitted. The submission is supported by Outlook
Therapeutics’ wet AMD clinical program, which consists of three
clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010
ophthalmic bevacizumab is approved, Outlook Therapeutics expects to
commercialize it as the first and only FDA-approved ophthalmic
formulation of bevacizumab for use in treating retinal diseases in
the United States, United Kingdom, Europe, Japan, and other
markets. As part of the Company’s multi-year commercial planning
process, Outlook Therapeutics and Cencora, formerly
AmerisourceBergen, entered into a strategic commercialization
agreement to expand the Company’s reach for connecting to retina
specialists and their patients. Cencora will provide third-party
logistics (3PL) services and distribution, as well as
pharmacovigilance services and other services in the United States.
For more information, please visit www.outlooktherapeutics.com.
CONTACTS:
Media Inquiries:Harriet UllmanVice
PresidentLaVoieHealthScienceT:
617.429.5475hullman@lavoiehealthscience.com
Investor Inquiries: Jenene Thomas Chief
Executive Officer JTC Team, LLC T: 833.475.8247
OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Nov 2023 to Dec 2023
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Dec 2022 to Dec 2023